Tirzepatide

Main evidence: Human clinical trials. Updated 2026-10-28.

What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.

Summary

Evidence-focused, review-only summary for informed discussion; not a prescription, personal dosing guide, or individualized medical advice. Australian brand labels, trial populations, and dated claims below are kept distinct.

What the sources say

The product information lists nausea, vomiting, diarrhoea, and other gastrointestinal effects; warns about pancreatitis and dehydration-related kidney problems; and notes increased hypoglycaemia risk when tirzepatide is used with insulin or sulfonylureas. This is a concise safety summary, not a complete label. (Manufacturer information; TGA Australian Product Information: Mounjaro (tirzepatide) solution for injection, 2024-09-20)
The TGA says available evidence may support a NAION safety signal for semaglutide, but did not support an association for tirzepatide; post-marketing reports nevertheless led to product-information warnings. Sudden or partial vision loss warrants urgent ophthalmological assessment. (Educator material (not peer reviewed); TGA Medicine Safety Update: GLP-1 RAs and rare vision disorder (NAION), 2026-07-23)
The TGA says reduced oral-contraceptive effectiveness during tirzepatide initiation or dose escalation could not be ruled out. As a precaution, it advises users of oral hormonal contraception to switch to a non-oral method or add a barrier method for 4 weeks after starting tirzepatide and for 4 weeks after each dose escalation. The TGA also says these medicines are not recommended during pregnancy. (Educator material (not peer reviewed); TGA Medicine Safety Update: Updated contraception advice for Mounjaro (tirzepatide) and pregnancy reminder, 2025-12-01)
The TGA aligned product warnings to monitor for new or worsening depression, suicidal thoughts or behaviours, or unusual mood changes. Its expert committee found the available evidence insufficient to support a causal association; the warning is not proof that tirzepatide causes these outcomes. (Educator material (not peer reviewed); TGA Medicine Safety Update: GLP-1 RAs — warnings aligned over potential risk of suicidal thoughts or behaviours, 2025-12-01)
The TGA warns that delayed gastric emptying can leave stomach contents despite routine fasting and may increase aspiration risk during general anaesthesia or deep sedation. Patients are advised to tell relevant clinicians, including anaesthetists, before a procedure. (Educator material (not peer reviewed); TGA Medicines Safety Update: Medicines containing GLP-1 and dual GIP/GLP-1 receptor agonists — anaesthesia/deep sedation warning, 2025-06-03)
The TGA identifies Mounjaro (tirzepatide) as an Australian prescription medicine approved for type 2 diabetes and chronic weight management. (Educator material (not peer reviewed); TGA Medicines Safety Update: Medicines containing GLP-1 and dual GIP/GLP-1 receptor agonists, 2025-06-03)
The TGA added Mounjaro for moderate-to-severe obstructive sleep apnoea in adults with obesity. (Educator material (not peer reviewed); TGA registration record: Mounjaro — obstructive sleep-apnoea indication (decision date), 2025-05-27)
The TGA registered Mounjaro for chronic weight management in adults as an adjunct to reduced-calorie diet and increased activity: BMI at least 30, or BMI at least 27 and below 30 with a weight-related comorbidity. (Educator material (not peer reviewed); TGA registration record: Mounjaro — chronic weight-management indication (decision date), 2024-09-09)

Sources

Dosing, stacking and protocol details are not published here.